Comparative Pharmacology
Head-to-head clinical analysis: DIUPRES 250 versus REGROTON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIUPRES 250 versus REGROTON.
DIUPRES-250 vs REGROTON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diupres-250 is a combination of hydrochlorothiazide (a thiazide diuretic) and reserpine (a Rauwolfia alkaloid). Hydrochlorothiazide inhibits the Na+/Cl- cotransporter in the distal convoluted tubule of the kidney, increasing excretion of sodium and water. Reserpine depletes catecholamines and serotonin from presynaptic nerve terminals by irreversibly binding to vesicular monoamine transporter (VMAT), leading to reduced sympathetic outflow and hypotension.
Regroton is a combination of reserpine and chlorthalidone. Reserpine depletes catecholamines from peripheral sympathetic nerve endings by inhibiting vesicular monoamine transporter 2 (VMAT2), leading to vasodilation and reduced heart rate. Chlorthalidone is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
1 tablet (containing 250 mg chlorothiazide and 0.125 mg reserpine) orally once daily, increased to 2 tablets daily if needed.
1 tablet (25 mg chlorthalidone / 50 mg metoprolol) orally once daily.
None Documented
None Documented
Hydroflumethiazide: 6-18 hours (prolonged in renal impairment). Reserpine: 50-100 hours (biphasic; terminal phase).
Terminal elimination half-life: 9-11 hours (mean 10 hours); clinical context: supports once-daily dosing in hypertension, steady-state reached in 3-4 days
Renal: approximately 50% of hydroflumethiazide is excreted unchanged in urine; reserpine is extensively metabolized with <1% excreted unchanged. Fecal: minimal.
Renal: 70-80% (50% as unchanged drug, 20-30% as metabolites); Fecal: <5%
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination